February 13, 2026 11:04 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers | Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Covaxin supplied to 18 states directly since May 1: Bharat Biotech

| @indiablooms | May 12, 2021, at 05:24 am

New Delhi/IBNS: Vaccine maker Bharat Biotech on Tuesday informed that it has directly supplied Covaxin to 18 states since May 1.

The pharmaceutical brand also urged people to get vaccinated assuring that it will continue a steady supply of vaccines to the states.

"COVAXIN® has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine. Get yourself and your loved ones vaccinated," the company said in a statement.

The company is supplying its vaccine directly to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu and Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh, and West Bengal.

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research (ICMR).

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

On April 29, Bharat Biotech reduced the price of Covaxin from Rs 600 per dose to Rs 400 for the state governments in view of the challenges faced by the already overstretched health system, the company had said.

The vaccination programme in India which started on Jan 16, was last month widely expanded to include citizens above 18 years of age as a part of the Centre's Liberalised Pricing & Accelerated National COVID-19 Vaccination strategy.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.